CA2159091C - Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses - Google Patents

Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses Download PDF

Info

Publication number
CA2159091C
CA2159091C CA002159091A CA2159091A CA2159091C CA 2159091 C CA2159091 C CA 2159091C CA 002159091 A CA002159091 A CA 002159091A CA 2159091 A CA2159091 A CA 2159091A CA 2159091 C CA2159091 C CA 2159091C
Authority
CA
Canada
Prior art keywords
alkyl
aryl
buspirone
group
c6h4ch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002159091A
Other languages
English (en)
French (fr)
Other versions
CA2159091A1 (en
Inventor
Richard J. Sharpe
Stephen J. Galli
Raj K. Razdam
Kenneth A. Arndt
Peter C. Meltzer
Howard P. Sard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/037,225 external-priority patent/US5631017A/en
Priority claimed from US08/037,271 external-priority patent/US5484788A/en
Application filed by Beth Israel Hospital Association filed Critical Beth Israel Hospital Association
Publication of CA2159091A1 publication Critical patent/CA2159091A1/en
Application granted granted Critical
Publication of CA2159091C publication Critical patent/CA2159091C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002159091A 1993-03-26 1994-03-28 Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses Expired - Fee Related CA2159091C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/037,225 US5631017A (en) 1993-03-26 1993-03-26 Topical application of buspirone for treatment of pathological conditions associated with immune responses
US08/037,225 1993-03-26
US08/037,271 US5484788A (en) 1993-03-26 1993-03-26 Buspirone as a systemic immunosuppressant
US08/037,271 1993-03-26
PCT/US1994/003353 WO1994022448A1 (en) 1993-03-26 1994-03-28 Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses

Publications (2)

Publication Number Publication Date
CA2159091A1 CA2159091A1 (en) 1994-10-13
CA2159091C true CA2159091C (en) 2006-12-19

Family

ID=26713927

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002159091A Expired - Fee Related CA2159091C (en) 1993-03-26 1994-03-28 Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses

Country Status (10)

Country Link
EP (1) EP0690715B1 (de)
JP (1) JPH09502699A (de)
AT (1) ATE241359T1 (de)
AU (1) AU692764B2 (de)
CA (1) CA2159091C (de)
DE (1) DE69432749T2 (de)
DK (1) DK0690715T3 (de)
ES (1) ES2201074T3 (de)
PT (1) PT690715E (de)
WO (1) WO1994022448A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
WO1997037659A1 (en) * 1996-04-08 1997-10-16 Sano Corporation Transdermal delivery device for azapirone compounds
EP1037627B1 (de) * 1998-07-14 2001-08-01 Alcon Laboratories, Inc. Verwendung von 11-(3-dimethylaminopropyliden)-6,11-dihydrodibenz[b,e]oxepin-2-essigsäure und deren pharmazeutisch annehmbaren salzen zur herstellung eines medikaments zur behandlung nicht-allergisch-bedingten augenentzündungen und zur prevention der okularen neovaskularisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
ATE135216T1 (de) * 1989-08-21 1996-03-15 Beth Israel Hospital Verwendung von spiperone-derivate zur immunosuppression
CA2077907C (en) * 1990-03-16 1998-06-09 Richard J. Sharpe Use of spiperone as an immunosuppressant and anti-inflammatory agent
SE513429C2 (sv) * 1992-06-03 2000-09-11 Syntello Inc Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer

Also Published As

Publication number Publication date
DE69432749T2 (de) 2004-04-08
ES2201074T3 (es) 2004-03-16
WO1994022448A1 (en) 1994-10-13
AU692764B2 (en) 1998-06-18
DK0690715T3 (da) 2003-09-22
AU6369294A (en) 1994-10-24
EP0690715A1 (de) 1996-01-10
JPH09502699A (ja) 1997-03-18
CA2159091A1 (en) 1994-10-13
EP0690715B1 (de) 2003-05-28
DE69432749D1 (de) 2003-07-03
ATE241359T1 (de) 2003-06-15
EP0690715A4 (de) 1997-09-03
PT690715E (pt) 2003-10-31

Similar Documents

Publication Publication Date Title
US5631017A (en) Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5703088A (en) Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5693645A (en) Use of spiperone or spiperone derivatives as immunosuppressant agents
US5244902A (en) Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5290783A (en) Use of spiperone derivatives as immunosuppressant agents
US5637314A (en) Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
RU2469723C2 (ru) Лекарственное средство, содержащее производное карбостирила и донепезил, для лечения болезни альцгеймера
US10335367B2 (en) Use of selected anticholinergic zwitterions
US5484788A (en) Buspirone as a systemic immunosuppressant
JP2003026575A (ja) 医薬組成物
CA2126678A1 (en) Use of spiperone or spiperone derivatives as immunosuppressant agents
WO2018148737A1 (en) 5-ht2a serotonin receptor serotonin receptor inverse agonists useful for the prophylaxis and treatment of parkinsonian symptoms associated with a neurodegenerative disease
CA2159091C (en) Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses
KR20150020160A (ko) 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물
US5574041A (en) Use of spiperone derivatives as immunosuppressant agents
JPH11514654A (ja) 外傷による脳損傷の治療方法
US20070191400A1 (en) Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives
MXPA06006685A (es) Uso de gaboxadol para tratar el insomnio.
JP2015500278A (ja) Ｔｒｐａ１アンタゴニストと抗コリン剤とを含む医薬組成物
JP7337791B2 (ja) デスロラタジン又はその塩を含有する医薬組成物
US20030166667A1 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
JPH08500120A (ja) 置換アザスピランを用いる乾癬の治療方法
EP4353228A1 (de) Verwendung von verbindungen zur hemmung oder abtötung von milben und behandlung des trockenen auges
KR20220043046A (ko) 스핑고신-1-인산 수용체 효능제의 용도
KR20140130695A (ko) 섬유근육통 및 만성 피로 증후군을 치료하기 위한 (1r,4r)-6''-플루오로-(N-메틸- 또는 N,N-디메틸-)-4-페닐-4'',9''-디하이드로-3''H-스피로-[사이클로헥산-1,1''-피라노[3,4,b]인돌]-4-아민

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed